Purespring Therapeutics’ Post

🚀 Breaking News in Biotech! 🚀 Critical Path Institute (C-Path) and CENTOGENE have signed an MoU to enhance collaboration in lysosomal disease research and drug development! 🧬💊 Key Highlights: -New Partnership: C-Path and Centogene join forces. -Focus Area: Advancing lysosomal disease research. -Objective: Accelerate the development of new treatments. Why It Matters: -Enhanced Research: Leveraging combined expertise to deepen our understanding of lysosomal diseases. -Innovative Solutions: Driving forward the development of groundbreaking therapies. -Global Impact: Aiming to improve health outcomes for patients worldwide. #Biotech #HealthcareInnovation #LysosomalDisease #DrugDevelopment #MedicalResearch #CPath #Centogene #RareDiseases #PharmaPartnerships #ScientificBreakthroughs

PolTREG is one of a crop of cutting-edge firms that has made Poland a hotbed for biotech innovation, an article in In Vivo says, fully deserving the attention of U.S. investors. PolTREG plays a prominent role in the article in this widely read international magazine. Chief Executive Officer Piotr Trzonkowski in an interview talked about the exciting outlook for Treg cellular therapies, with which we one day hope to be able to prevent type-1 diabetes (T1D), and tackle a range of other autoimmune diseases. PolTREG has had a series of successes. Positive results from a long-term data study has opened the way for a pivotal trial for our lead asset PTG-007 in early-onset T1D. We are also planning to launch three new clinical studies in other indications soon. Subscribers can read the article here: https://lnkd.in/dS64K949 Citeline David Wild #biotech #biotechnology #celltherapy #cellandgenetherapy #autoimmunedisease #diabetes #type1diabetes

While survival and function are two crucial endpoints for rare diseases such as Amyotrophic lateral sclerosis (ALS), it is equally important for efficient drug development overcoming regulatory challenges. What breakthroughs are on the cusp for rare and orphan diseases that make you hopeful for patients? Join the panel discussion led by Mike Ward, Global Head of Thought Leadership, Life Science & Healthcare at Clarivate, Rob Etherington, CEO at Clene Nanomedicine, Inc. and Neil McFarlane, CEO at Zevra Therapeutics to examine the dynamic role data might play in rare disease and personalized medicine. View the on-demand webinar to determine what companies need to be doing to address this complex and evolving field, here: https://lnkd.in/eHsQxAMw #raredisease #regulatory #IRA #ALS

Factual Fridays 💡 Membrane proteins are involved in numerous essential cellular functions, such as communication, signal transduction, and transport, and play a major role in various disease processes, making them key targets for therapeutic intervention. 💊 💉 Despite their significance in disease prevention and treatment, studying membrane proteins remains a considerable challenge, driving ongoing drug discovery and development efforts. #membraneproteins #biotechnology #proteinscience #drugdevelopment #polymerscience #polymernanodiscs #innovation #nanosene

We are pleased to highlight recent research co-authored by our CSO, Dr. Semen Yesylevskyy. The study, "A novel fatty acid analogue triggers CD36–GPR120 interaction and exerts anti-inflammatory action in endotoxemia," investigates the anti-inflammatory properties of a promising new compound, NKS3. This compound significantly reduces inflammation markers in various models, making it a potential therapeutic agent for diseases characterized by high inflammation, such as sepsis and acute lung injuries, which are among the leading causes of death globally. The study highlights NKS3's ability to interact with the CD36 and GPR120 receptors, revealing a promising dual binding mechanism that could modulate the inflammatory response more effectively than current treatments. By inhibiting key pathways like NF-kB, NKS3 shows potential in reducing the cytokine storms often fatal in septic shock. These findings open up new avenues for the development of treatments for chronic and acute inflammatory diseases. This research is part of our ongoing efforts to develop scientific solutions that address inflammation-related health issues. As we continue to analyze the potential of NKS3, we are committed to further exploring how these findings can be integrated into broader health strategies and treatments. You can find the link to the full article in the comment section. #Inflammation #DrugDiscovery #BiotechInnovation #HealthcareScience #Pharma #Biotech #MedicalResearch #PharmaInnovation

Japan’s ten hottest biotech companies in healthcare "Japan boasts one of the highest life expectancies in the world, and, faced with a rapidly aging population, is witnessing a growing burden of chronic conditions including cardiovascular disease and type 2 diabetes. For this reason, the Japanese healthcare authorities are encouraging research into the treatment and prevention of these diseases, in addition to promoting the potential of regenerative medicine." Chordia Therapeutics Inc Heartseed Inc. LUCA Science --- https://lnkd.in/eMhJW9N2 Modulus Discovery Noile-Immune Biotech --- https://lnkd.in/ev2GR5vm Peptidream Raqualia Pharma --- https://lnkd.in/eMVeyQFh Restore Vision SanBio, Inc. StemRIM --- https://lnkd.in/e-xK-CS5 https://lnkd.in/eZ__mww2

💰💊 Pharmacogenomics and Cost Savings! 💊💰 Did you know that pharmacogenomics can lead to significant cost savings for patients? 🌟 By tailoring medication treatments based on individual genetic makeup, we can optimise drug selection, reduce adverse reactions, and improve treatment efficacy. 💡 With personalized medicine, patients are less likely to undergo trial-and-error approaches, ultimately saving on healthcare expenses associated with ineffective treatments and hospitalizations. 📉 Say goodbye to wasted resources and hello to targeted therapies designed just for you! Experience the financial benefits of pharmacogenomics with Genetix. 💰💊 #CostSavings #Pharmacogenomics #PersonalizedMedicine #GenetixInnovates

With recent advances in structure-based #drugdiscovery approaches, oral #smallmolecule drugs now have the potential to surpass the manufacturing scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. Learn more about how we're harnessing structure-based drug design, coupled with our advanced computational technologies and world-class expertise, to potentially treat diseases like type 2 #diabetes, #obesity, and #cardiopulmonary diseases below. https://lnkd.in/dzthZsh3

Johnson & Johnson's experimental autoimmune drug, nipocalimab, demonstrated success in a Phase 3 study for treating generalized myasthenia gravis, offering significant benefits compared to a placebo. The drug works by targeting disease-causing antibodies, leading to improved daily functioning and quality of life for patients. J&J is optimistic about the potential approval of nipocalimab for this condition and aims to expand its usage across multiple indications, projecting substantial revenue growth. #AutoimmuneDisease #Nipocalimab #MyastheniaGravis #AntibodyTherapy #HealthcareInnovation Read more here: https://lnkd.in/egiNWQNN BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X.

Last week, our CSO Martijn van de Bunt, PhD, presented preclinical data at the 60th European Association for the Study of Diabetes e.V. (EASD) Annual Meeting, showcasing the novel intestinal mechanism-of-action of lipidated IL-22 for weight loss. This unique approach complements current weight loss therapies and holds promising potential for #obesity management. Check out the key takeaways from his presentation below! #EASD2024 #Diabetes #Biotech